45 results about "Underlying disease" patented technology

The invention features methods of treating visceral pain in humans by administering an effective amount of a 5HT1B or 5HT1D receptor agonist, (e.g., a triptan). These methods can be used, for example, to treat a human suffering from visceral pain secondary to an underlying disease of a visceral organ, such as pancreatitis. Visceral pain treatable by the methods of the invention may also be secondary to a disease of the liver, kidney, ovary, uterus, bladder, bowel, stomach, esophagus, duodenum, intestine, colon, spleen, pancreas, appendix, heart, or peritoneum.

Intractable hiccups are debilitating and are usually a result of underlying disease. A method of treating chronic hiccups is provided, comprising the steps of applying a peripheral nerve stimulator to the vagus nerve at a predetermined frequency, pulse width, amplitude, and duration; monitoring the occurrence of hiccups in response to said stimulation; and adjusting said frequency, pulse width, amplitude, and duration to reduce the occurrence of said hiccups. The vagus nerve stimulation methods disclosed herein have provided complete resolution to date with a patient with intractable hiccups occurring after a posterior fossa stroke.

A biological chip device having a biologic materials component according to embodiments of the invention may provide the ability to sense levels of blood parameters (e.g., glucose, insulin, and glucagon levels) in a patient. In certain embodiments of the invention, a device may include therapeutic abilities in which a portion of the biologic materials component produces a drug to treat the underlying disease in response to measured or sensed blood parameter levels.

The present invention concerns the novel use of compounds of the Formula I: for treating allodynia as major and unique pain symptom independent of the nature of an underlying disease, but that is often related to neuropathic pain or other different types of chronic or phantom pain.

A method of treating weight loss due to underlying disease in a patient the method comprising administering to the patient an effective amount of an agent which reduces sympathetic nervous system activity. A method of treating weight loss due to underlying disease in a patient the 10 method comprising administering to the patient an effective amount of any one or more of the following: a compound which inhibits the effect of aldosterone such as an aldosterone antagonist; a chymase inhibitor; a cathepsin B inhibitor; a 13 receptor blocker; an imidazoline receptor antagonist; a centrally acting tx receptor antagonist; a peripherally acting ct receptor antagonist; a ganglion blocking agent; a drug that has an effect on cardiovascular reflexes and thereby reduce SNS activity such as an opiate; scopolamine; an endothelin receptor antagonist; and a xanthine oxidase inhibitor. The methods are particularly useful in treating cardiac cachexia.

A method for determining a disease state prediction, relating to a potential disease or medical condition of a subject, includes accessing a set of subject images, the subject images capturing a part of a subject's body, and accessing a set of clinical factors from the subject. The clinical factors are collected by a device or a medical practitioner substantially contemporaneously with the capture of the subject images. The subject images are inputted into an image model to generate disease metrics for disease prediction for the subject. The disease metrics generated by the image model and the clinical factors are inputted into a classifier to determine the disease state prediction, and the disease state prediction is returned.

The invention provides an antigen stimulant for detecting mycobacterium tuberculosis infection, and a kit comprising the antigen stimulant. The invention also provides an application of the antigen stimulant in reagents for detecting mycobacterium tuberculosis infection. The antigen stimulant comprises at least one polypeptide or analogues thereof in polypeptides shown as the sequences 1-11 in a sequence table, wherein the polypeptides respectively come from tuberculosis specific antigen polypeptides ESAT-6 and tuberculosis specific antigen polypeptides CFP-10. According to the antigen stimulant provided by the invention, peripheral blood T lymphocytes of tuberculosis infection patients can be effectively stimulated to generate IFN-gamma, so that the tuberculosis infection can be diagnosed at high sensitivity and high specificity, and the influence on BCC inoculation or other underlying diseases can be avoided.

A method of treating weight loss due to underlying disease in a patient, the method comprising administering to the patient an effective amount of an agent which reduces sympathetic nervous system activity. A method of treating weight loss due to underlying disease in a patient the method comprising administering to the patient an effective amount of any one or more of the following: a compound which inhibits the effect of aldosterone such as an aldosterone antagonist; a chymase inhibitor; a cathepsin B inhibitor; a β receptor blocker; an imidazoline receptor antagonist; a centrally acting α receptor antagonist; a peripherally acting α receptor antagonist; a ganglion blocking agent; a drug that has an effect on cardiovascular reflexes and thereby reduces SNS activity such as an opiate; scopolamine; an endothelin receptor antagonist; and a xanthine oxidase inhibitor. The methods are particularly useful in treating cardiac cachexia.

The invention provides a stroke emergency screening supervision Internet of doctors and an application method thereof. The system comprises a stroke emergency screening Internet of Things system, a stroke emergency command and dispatch management system, a stroke emergency Internet of Things system, an intensive care system and a stroke emergency screening supervision information system. The stroke emergency screening supervision Internet of doctors focuses on the screening, prevention, treatment and health management of stroke, checks underlying diseases by establishing a medical and health cooperation platform and using the medical Internet of Things as the main means, constructs a new mode of accurate medical treatment and health management under the guidance of medical specialists, andactively screens stroke patients. The hospital receiving an emergency request makes response to the emergency demand in time, follows the subsequent therapeutic measures and guides the subsequent treatment so as to reasonable handle the major public health threats caused by stroke, improve the overall treatment efficiency and level of the patients, and reduce the incidence, recurrence rate, disability rate and mortality of stroke.

Pro-apoptotic agents such as ligands and agonists of agonistic TRAIL receptors can induce or increase apoptosis of cells that cause fibrosis and underlying diseases such as liver, pancreatic, lung and skin diseases characterized by fibrosis, cirrhosis, or complications thereof. The compositions and methods can be used to selectively remove activated hepatic stellate cells (HSCs), the originators of liver fibrosis and cirrhosis, and activated pancreatic stellate cells (PSCs), the originators of pancreas fibrosis and pancreatitis, and can be effective to reduce or prevent further chronic fibrosis by simultaneously reducing multiple fibrosis-associated molecules secreted or induced by such activated stellate cells. The compositions are typically effective to target agonistic TRAIL receptors such as TRAIL-R1 / DR4 and TRAIL-R2 / DR5 that are selectively expressed in activated HSCs and PSCs in physiological conditions. Ligands and agonists that can be used to target agonistic TRAIL receptors include, but are not limited to, TRAIL-R1 / DR4 and / or TRAIL-R2 / DR5 agonists.

Pro-apoptotic agents such as ligands and agonists of agonistic TRAIL receptors can induce or increase apoptosis of cells that cause fibrosis and underlying diseases such as liver, pancreatic, lung and skin diseases characterized by fibrosis, cirrhosis, or complications thereof. The compositions and methods can be used to selectively remove activated hepatic stellate cells (HSCs), the originators of liver fibrosis and cirrhosis, and activated pancreatic stellate cells (PSCs), the originators of pancreas fibrosis and pancreatitis, and can be effective to reduce or prevent further chronic fibrosis by simultaneously reducing multiple fibrosis-associated molecules secreted or induced by such activated stellate cells. The compositions are typically effective to target agonistic TRAIL receptors such as TRAIL-R1 / DR4 and TRAIL-R2 / DR5 that are selectively expressed in activated HSCs and PSCs in physiological conditions. Ligands and agonists that can be used to target agonistic TRAIL receptors include, but are not limited to, TRAIL-R1 / DR4 and / or TRAIL-R2 / DR5 agonists.

A method and apparatus for administering eye tests to identify cone sensitivity loss associated with hereditary and acquired color vision loss which may be used for early detection, progress, treatment, and monitoring of eye conditions, traumatic brain injury, optic neuritis, systemic and neurological diseases including Glaucoma, Retinopathy, Age-Related Macular Degeneration, Multiple Sclerosis, Alzheimer's Disease, and Parkinson's Disease and retinal toxicity. Particularly, the method and apparatus disclosed uses a Cone Contrast Test (CCT) to test individuals for hereditary or acquired color vision loss associated with (a) early signs of potential disease / damage / toxicity in an effort to (i) provide opportunity for treatment, and (ii) prevent permanent eye damage, and (b) monitor progress and treatment of such disease / damage / toxicity. The system comprises a computer system including an input device and a display device, and the accuracy and repeatability of the testing is provided by repeated calibration using a colormeter.

The invention provides a medical care large data analysis and treatment system and method based on web page browsing. The method comprises the following steps: searching out the contact information of a patient from the medical data of the patient; according to the contact information of the patient, acquiring medical care web pages browed by the patient from a telecommunication operator; performing analysis on the medical care web pages so as to obtain a second disease set that the patient pays close attention to when browsing the medical care web pages; according to the second disease set and a first disease set, acquiring a third disease set that the patient suffers from potential diseases; acquiring the contact information of a doctor relative to the third disease set from a hospital information system, and notifying the doctor to make a prevention scheme for preventing the corresponding diseases in the third disease set; sending the prevention scheme to a client held by the patient so as to remind the patient of paying close attention to prevention of potential diseases. When the medical care large data analysis and treatment system and method disclosed by the invention are implemented, the risk that the patient suffers from potential diseases can be known, the prevention scheme can be timely made, and the risk that the patient suffers from the potential diseases is reduced.

The present disclosure relates to the treatment of impulsive aggression with molindone as an add-on therapy where patients are already receiving treatment for the underlying disease or disorder, e.g. attention deficit hyperactivity disorder (ADHD), bipolar disorder, autism, Tourette's syndrome or post traumatic stress disorder (PTSD), using evidence-based impulsive aggression testing methodologies and systems.

The invention discloses a method and system of processing and analyzing diagnosis information, and relates to the technical field of medical system. The method of processing and analyzing diagnosis information includes the following steps: establishing characteristic space and label space through a plurality of sample characteristics and label information, and establishing the characteristic vector and the first label vector of the sample; calculating the occurrence number of each label information; calculating the occurrence number that every two label information occur in one sample at the same time; calculating the similarity of every two label information, and establishing a similarity matrix of label-label; reconstructing the first label vector to obtain the second label vector, and according to the second label vector, calculating the occurrence probability of the label information of the target sample; and selecting the preset number of label information as the recommended labelinformation of the target sample. The method and system of processing and analyzing diagnosis information can form the characteristic space and the label information by means of the characteristics corresponding to the disease of a patient, can effectively discover more underlying diseases by means of correlation between the diseases and the complication of the diseases, and can improve the accuracy of diagnosis decision support.

It has been discovered that granulocyte macrophage colony stimulating factor (“GM-CSF”) promotes migration of activated (but not differentiating) keratinocytes to wound sites. It was also discovered that GM-CSF increases the quantity and improves the quality of collagen. This growth factor specifically increases migration of keratinocytes of the “wound” phenotype but does not have significant effects upon differentiated keratinocytes. Examples demonstrate reversal of skin impairment in multiple animal models of diabetic skin imparment when provided in an effective amount over an effective time period. The examples also demonstrate the efficacy of the formulations in cosmetic applications. A preferred formulation is a sustained release formulation that delivers sufficient growth factor to the skin and the underlying tissue thereof to increase the rate of keratinocyte migration, as well as collagen deposition and fibroblast proliferation, in the skin to promote rejuvenation of skin injuries resistant to repair due to underlying disease, such as diabetes, or aging.

Methods and apparatus for identifying disease status according to various aspects of the present invention include analyzing the levels of one or more biomarkers. The methods and apparatus may use biomarker data for a condition-positive cohort and a condition-negative cohort and select multiple relevant biomarkers from the plurality of biomarkers. The system may generate a statistical model for determining the disease status according to differences between the biomarker data for the relevant biomarkers of the respective cohorts. The methods and apparatus may also facilitate ascertaining the disease status of an individual by producing a composite score for an individual patient and comparing the patient's composite score to one or more thresholds for identifying potential disease status.

Pro-apoptotic agents such as ligands and agonists of agonistic TRAIL receptors can induce or increase apoptosis of cells that cause fibrosis and underlying diseases such as liver, pancreatic, lung and skin diseases characterized by fibrosis, cirrhosis, or complications thereof. The compositions and methods can be used to selectively remove activated hepatic stellate cells (HSCs), the originators of liver fibrosis and cirrhosis, and activated pancreatic stellate cells (PSCs), the originators of pancreas fibrosis and pancreatitis, and can be effective to reduce or prevent further chronic fibrosis by simultaneously reducing multiple fibrosis-associated molecules secreted or induced by such activated stellate cells. The compositions are typically effective to target agonistic TRAIL receptors such as TRAIL-R1 / DR4 and TRAIL-R2 / DR5 that are selectively expressed in activated HSCs and PSCs in physiological conditions. Ligands and agonists that can be used to target agonistic TRAIL receptors include, but are not limited to, TRAIL-R1 / DR4 and / or TRAIL-R2 / DR5 agonists.

The present invention provides methods, compositions, and kits for treating intestinal hyperpermeability in a subject in need thereof, including conditions such as hyperglycemia and underlying diseases such as diabetes, autism, fibromyalgia, inflammatory bowel disease (IBD), graft versus host disease (GVHD), HIV / AIDS, multiple organ dysfunction syndrome, irritable bowel syndrome (IBS), celiac disease, eczema, psoriasis, acute pancreatitis, Parkinson's disease, depression, chronic fatigue syndrome, asthma, multiple sclerosis, arthritis, ankylosing spondylitis, nonalcoholic fatty liver disease, alcoholic cirrhosis, environmental enteropathy, or kwashiorkor.

Embodiments of the invention provide techniques which utilize crowdsourced reports of environmental conditions to predict and / or prevent disease outbreaks. In one aspect, a method comprises receiving one or more crowdsourced reports about one or more environmental conditions; inferring one or more input parameters for at least one disease outbreak model based at least in part on the one or more crowdsourced reports; applying the at least one disease outbreak model to at least the one or more inferred parameters to predict one or more characteristics of at least one potential disease outbreak associated with the reported one or more environmental conditions; and, based at least in part on the predicted one or more characteristics, implementing one or more corrective actions to mitigate the at least one potential disease outbreak.

The invention relates to a chronic disease patient diet management scheme push method and device. The method comprises the steps that the physical condition data of the patient are acquired, wherein the physical condition data include the height, the body weight and the physical labor intensity; the daily calories required by the patient are determined according to the physical condition data; theunderlying disease of the patient is acquired; the diet scheme of the patient is determined according to the daily calories required by the patient and the underlying disease, wherein the diet schemeincludes the daily food types required by the patient and the corresponding food weight of each food type; and the diet scheme of the patient is outputted to the terminal equipment of the patient. According to the technical scheme, the diet scheme having reasonable calories, balanced nutrition, multiple types of collocation and free changes can be automatically matched for the patient so that daily performance and long-term persistence can be facilitated for the patient and great control of the disease can be facilitated.

A method and apparatus for administering eye tests to identify cone sensitivity loss associated with hereditary and acquired color vision loss which may be used for early detection, progress, treatment, and monitoring of eye conditions, traumatic brain injury, optic neuritis, systemic and neurological diseases including Glaucoma, Retinopathy, Age-Related Macular Degeneration, Multiple Sclerosis, Alzheimer's Disease, and Parkinson's Disease and retinal toxicity. Particularly, the method and apparatus disclosed uses a Cone Contrast Test (CCT) to test individuals for hereditary or acquired color vision loss associated with (a) early signs of potential disease / damage / toxicity in an effort to (i) provide opportunity for treatment, and (ii) prevent permanent eye damage, and (b) monitor progress and treatment of such disease / damage / toxicity. The system comprises a computer system including an input device and a display device, and the accuracy and repeatability of the testing is provided by repeated calibration using a colormeter.

The identification of 101 genes upregulated or differentially expressed by mature human oocytes is provided herein. These genes and the corresponding gene products will facilitate a greater understanding of oogenesis, folliculogenesis, fertilization, and embryonic development. In addition these genes and the corresponding gene products can be used to effect dedifferentiation and / or transdifferentiation of desired somatic cells. The resultant dedifferentiated cells and somatic cells derived therefrom can be used in cell therapies such as in the treatment of cancer, autoimmunity, and other diseases wherein specific types of cells such as hematopoietic cells may be depleted because of the underlying disease or the treatment of the disease.Also, a core group of 66 transcripts was identified by intersecting significantly up-regulated genes of the human oocyte with those from the mouse oocyte and from human and mouse embryonic stem cells. Within the up-regulated probe sets, the top overrepresented categories were related to RNA and protein metabolism, followed by DNA metabolism and chromatin modification. This invention therefore provides a comprehensive expression baseline of genes expressed in in vivo matured human oocytes. Further understanding of the biological role of these genes will also expand knowledge on meiotic cell cycle, fertilization, chromatin remodeling, lineage commitment, pluripotency, tissue regeneration, and morphogenesis.

A method for determining a disease state prediction, relating to a potential disease or medical condition of a subject, includes accessing a set of subject images, the subject images capturing a part of a subject's body, and accessing a set of clinical factors from the subject. The clinical factors are collected by a device or a medical practitioner substantially contemporaneously with the capture of the subject images. The subject images are inputted into an image model to generate disease metrics for disease prediction for the subject. The disease metrics generated by the image model and the clinical factors are inputted into a classifier to determine the disease state prediction, and the disease state prediction is returned.

It has been discovered that granulocyte macrophage colony stimulating factor (“GM-CSF”) promotes migration of activated (but not differentiating) keratinocytes to wound sites. It was also discovered that GM-CSF increases the quantity and improves the quality of collagen. This growth factor specifically increases migration of keratinocytes of the “wound” phenotype but does not have significant effects upon differentiated keratinocytes. Examples demonstrate reversal of skin impairment in multiple animal models of diabetic skin imparment when provided in an effective amount over an effective time period. The examples also demonstrate the efficacy of the formulations in cosmetic applications. A preferred formulation is a sustained release formulation that delivers sufficient growth factor to the skin and the underlying tissue thereof to increase the rate of keratinocyte migration, as well as collagen deposition and fibroblast proliferation, in the skin to promote rejuvenation of skin injuries resistant to repair due to underlying disease, such as diabetes, or aging.

The invention discloses a traumatic injury drug and a preparation method thereof, and relates to the field of Chinese medicine. According to the traumatic injury drug, more than ten Chinese herbs, including pseudo-ginsengs, cortex acanthopanacis, eucommia bark, common clubmoss herbs, olibanum, myrrh, dragon blood, rhizomes of east Asian tree ferns, centipedes, caulis spatholobi and others, are carefully selected, and after reasonable compatibility and scientific processing, the traumatic injury drug is externally applied to a wound, so that the functions of promoting blood circulation to remove blood stases, relieving swelling and pains, union of fractured bones and tendons and clearing and activating the channels and collaterals are realized; by arousing the regeneration capacity of humanbody tissue, microcirculation of the wound is improved, and the aims of promoting porosis and accelerating wound healing and functional recovery are realized. Compared with a traditional therapy method, the traumatic injury drug has the advantages that the effect of therapy is good, costs are low, rehabilitation time is short, and there are no sequelae after rehabilitation, and has prominent treatment effects on older senile patients with weak physique and complex underlying diseases.

Methods for identifying to which patients a drug should be administered, based on underlying drug mechanism of action, are provided. Machine learning techniques are used to determine that patient's underlying disease pathway includes drug mechanism of action target; the drug is then administered, based on this determination. Multiple types of data, including demographic, physiological, treatment, and clinical notes data, can be used to train a classification component. Multiple patient populations can be used as sources of patient data for training classification component. Data input requirements, dimensionality, and performance metrics may be optimized.